Allied World Assurance Company Holdings (AWH)

$1.49

-0.01

(-0.67%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $1.41
    $1.54
    $1.49
    downward going graph

    5.37%

    Downside

    Day's Volatility :8.44%

    Upside

    3.25%

    downward going graph
  • $0.86
    $6.75
    $1.49
    downward going graph

    42.28%

    Downside

    52 Weeks Volatility :87.26%

    Upside

    77.93%

    downward going graph

Returns

PeriodAllied World Assurance Company HoldingsSector (Health Care)Index (Russel 2000)
3 Months
-54.91%
6.5%
0.0%
6 Months
-71.64%
7.1%
0.0%
1 Year
-40.48%
9.8%
0.0%
3 Years
-97.89%
14.2%
-20.2%

Highlights

Market Capitalization
20.1M
Book Value
- $0.11
Earnings Per Share (EPS)
-1.41
PEG Ratio
0.0
Wall Street Target Price
5.25
Profit Margin
-163.95%
Operating Margin TTM
-218.77%
Return On Assets TTM
-115.77%
Return On Equity TTM
-723.45%
Revenue TTM
9.0M
Revenue Per Share TTM
0.89
Quarterly Revenue Growth YOY
-7.000000000000001%
Gross Profit TTM
4.3M
EBITDA
-17.1M
Diluted Eps TTM
-1.41
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.3
EPS Estimate Next Year
-0.84
EPS Estimate Current Quarter
-0.33
EPS Estimate Next Quarter
-0.3

Analyst Recommendation

Buy
    57%Buy
    42%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Allied World Assurance Company Holdings(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
4
4
4
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 252.35%

Current $1.49
Target $5.25

Company Financials

FY18Y/Y Change
Revenue
3.1M
↓ 2.18%
Net Income
-11.4M
↑ 8.33%
Net Profit Margin
-372.45%
↓ 36.12%
FY19Y/Y Change
Revenue
4.5M
↑ 48.64%
Net Income
-14.8M
↑ 30.55%
Net Profit Margin
-327.13%
↑ 45.32%
FY20Y/Y Change
Revenue
4.7M
↑ 2.49%
Net Income
-17.6M
↑ 18.76%
Net Profit Margin
-379.06%
↓ 51.93%
FY21Y/Y Change
Revenue
6.8M
↑ 46.46%
Net Income
-31.7M
↑ 79.86%
Net Profit Margin
-465.5%
↓ 86.44%
FY22Y/Y Change
Revenue
8.2M
↑ 20.14%
Net Income
-21.6M
↓ 31.96%
Net Profit Margin
-263.62%
↑ 201.88%
FY23Y/Y Change
Revenue
9.2M
↑ 11.85%
Net Income
-16.7M
↓ 22.64%
Net Profit Margin
-182.32%
↑ 81.3%
Q3 FY22Q/Q Change
Revenue
2.1M
↑ 0.29%
Net Income
581.0K
↓ 107.03%
Net Profit Margin
28.04%
↑ 428.14%
Q4 FY22Q/Q Change
Revenue
2.2M
↑ 3.91%
Net Income
-4.6M
↓ 899.48%
Net Profit Margin
-215.75%
↓ 243.79%
Q1 FY23Q/Q Change
Revenue
2.3M
↑ 7.57%
Net Income
-6.3M
↑ 36.47%
Net Profit Margin
-273.7%
↓ 57.95%
Q2 FY23Q/Q Change
Revenue
2.5M
↑ 7.56%
Net Income
-2.3M
↓ 63.45%
Net Profit Margin
-93.01%
↑ 180.69%
Q3 FY23Q/Q Change
Revenue
2.2M
↓ 11.0%
Net Income
-4.7M
↑ 103.11%
Net Profit Margin
-212.27%
↓ 119.26%
Q1 FY24Q/Q Change
Revenue
2.1M
↓ 3.92%
Net Income
-3.1M
↓ 34.36%
Net Profit Margin
-145.02%
↑ 67.25%
FY18Y/Y Change
Total Assets
11.4M
↑ 52.17%
Total Liabilities
4.3M
↑ 4.06%
FY19Y/Y Change
Total Assets
13.8M
↑ 21.21%
Total Liabilities
5.1M
↑ 19.6%
FY20Y/Y Change
Total Assets
19.6M
↑ 41.78%
Total Liabilities
9.9M
↑ 94.22%
FY21Y/Y Change
Total Assets
41.1M
↑ 109.53%
Total Liabilities
10.9M
↑ 10.33%
FY22Y/Y Change
Total Assets
17.4M
↓ 57.71%
Total Liabilities
10.6M
↓ 2.43%
FY23Y/Y Change
Total Assets
6.3M
↓ 63.96%
Total Liabilities
8.6M
↓ 18.93%
Q4 FY22Q/Q Change
Total Assets
17.4M
↓ 27.44%
Total Liabilities
10.6M
↓ 16.62%
Q1 FY23Q/Q Change
Total Assets
11.5M
↓ 33.83%
Total Liabilities
10.7M
↑ 0.25%
Q2 FY23Q/Q Change
Total Assets
7.7M
↓ 32.85%
Total Liabilities
8.2M
↓ 22.69%
Q3 FY23Q/Q Change
Total Assets
8.7M
↑ 12.2%
Total Liabilities
9.3M
↑ 13.01%
Q1 FY24Q/Q Change
Total Assets
6.3M
-
Total Liabilities
8.6M
-
FY18Y/Y Change
Operating Cash Flow
-9.4M
↑ 15.23%
Investing Cash Flow
-113.0K
↑ 88.33%
Financing Cash Flow
13.3M
↑ 56.74%
FY19Y/Y Change
Operating Cash Flow
-13.0M
↑ 38.42%
Investing Cash Flow
-132.0K
↑ 16.81%
Financing Cash Flow
15.4M
↑ 16.09%
FY20Y/Y Change
Operating Cash Flow
-14.7M
↑ 13.64%
Investing Cash Flow
-490.0K
↑ 271.21%
Financing Cash Flow
20.2M
↑ 30.51%
FY21Y/Y Change
Operating Cash Flow
-27.4M
↑ 85.93%
Investing Cash Flow
-184.0K
↓ 62.45%
Financing Cash Flow
48.4M
↑ 140.07%
Q3 FY22Q/Q Change
Operating Cash Flow
-8.6M
↑ 36.93%
Investing Cash Flow
-53.0K
↑ 130.43%
Financing Cash Flow
7.6M
↓ 16014.58%
Q4 FY22Q/Q Change
Operating Cash Flow
-7.1M
↓ 18.03%
Investing Cash Flow
-4.0K
↓ 92.45%
Financing Cash Flow
-94.0K
↓ 101.23%
Q1 FY23Q/Q Change
Operating Cash Flow
-5.7M
↓ 19.36%
Investing Cash Flow
-8.0K
↑ 100.0%
Financing Cash Flow
-55.0K
↓ 41.49%
Q2 FY23Q/Q Change
Operating Cash Flow
-3.4M
↓ 40.12%
Investing Cash Flow
-4.0K
↓ 50.0%
Financing Cash Flow
134.0K
↓ 343.64%

Technicals Summary

Sell

Neutral

Buy

Allied World Assurance Company Holdings is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Allied World Assurance Company Holdings
Allied World Assurance Company Holdings
12.78%
-71.64%
-40.48%
-97.89%
101.21%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-3.67%
-10.34%
-15.37%
-31.35%
65.77%
Agilent Technologies Inc.
Agilent Technologies Inc.
1.42%
3.05%
5.07%
-10.16%
94.22%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
6.51%
8.62%
3.5%
12.36%
106.99%
Danaher Corp.
Danaher Corp.
6.51%
15.92%
1.97%
-6.92%
89.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
10.0%
7.5%
0.14%
-6.07%
45.29%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Allied World Assurance Company Holdings
Allied World Assurance Company Holdings
NA
NA
0.0
-1.3
-7.23
-1.16
NA
-0.11
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
45.67
45.67
4.75
11.06
0.72
0.23
NA
18.93
Agilent Technologies Inc.
Agilent Technologies Inc.
31.63
31.63
2.7
5.2
0.21
0.08
0.01
21.31
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
35.72
35.72
2.81
21.71
0.14
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
48.76
48.76
3.13
6.99
0.08
0.04
0.0
68.92
Iqvia Holdings Inc.
Iqvia Holdings Inc.
30.13
30.13
1.33
11.19
0.23
0.05
NA
36.83
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Allied World Assurance Company Holdings
Allied World Assurance Company Holdings
Buy
$20.1M
101.21%
NA
-163.95%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$38.8B
65.77%
45.67
23.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$38.9B
94.22%
31.63
18.84%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$219.4B
106.99%
35.72
14.2%
Danaher Corp.
Danaher Corp.
Buy
$191.9B
89.83%
48.76
17.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.3B
45.29%
30.13
9.39%

Insights on Allied World Assurance Company Holdings

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 2.49M → 2.13M (in $), with an average decrease of 7.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -4.70M → -3.08M (in $), with an average increase of 52.4% per quarter

  • Vs A

    In the last 1 year, Agilent Technologies Inc. has given 5.1% return, outperforming this stock by 45.6%

  • Vs TMO

    In the last 3 years, Allied World Assurance Company Holdings has experienced a drawdown of -97.9%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 87.7%

Institutional Holdings

  • Armistice Capital, LLC

    9.29%

  • Vanguard Group Inc

    2.23%

  • National Asset Management Inc

    1.01%

  • BlackRock Inc

    0.50%

  • Geode Capital Management, LLC

    0.48%

  • Northern Trust Corp

    0.27%

Company Information

vermillion, inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. the company’s initial in vitro diagnostic test, ova1®, was the first fda-cleared, protein-based in vitro diagnostic multivariate index assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. in march 2016 vermillion received fda clearance for overa™, a second generation ova1 test with significantly improved specificity and ease of use.

Organization
Allied World Assurance Company Holdings
Employees
64
CEO
Ms. Nicole Sandford C.P.A.
Industry
Health Technology

Discover More

FAQs